Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002130
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Long-Term Follow-On Safety Study of Four Doses of OPC-8212 Vesnarinone in HIV-Infected Persons
Sponsor:
Otsuka America Pharmaceutical
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Long-Term Follow-On Safety Study of Four Doses of OPC-8212 Vesnarinone in HIV-Infected Persons
Status:
COMPLETED
Status Verified Date:
1996-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study less than 12 months on continuous treatment of the drug
Detailed Description:
Patients who have completed a limited duration study less than 12 months of continuous treatment of vesnarinone on protocols FDA 234A or FDA 234B and who have no current signs or symptoms of AIDS-defining illnesses may roll over to this study and continue receiving their regimen of vesnarinone for 12 months beyond their original participation
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 22-93-253 | None | None | None |